Cases & Deals

  • Home
  • Practices
  • Astellas enters into strategic collaboration and exclusive option license agreement with ImmunoPrecise Antibodies Ltd.

Share

Astellas enters into strategic collaboration and exclusive option license agreement with ImmunoPrecise Antibodies Ltd.

March 2023

Client(s) Xyphos Biosciences, Inc.

Jones Day represented Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas Pharma Inc., "Astellas") in connection with a research collaboration and exclusive option license agreement with ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company. Under the terms of the agreement, the companies will jointly conduct research activities to identify and optimize proprietary LENSai in silico generated antibodies, targeting an undisclosed target in the tumor microenvironment, as potential therapeutic development candidates. Targeting this molecule has the potential to markedly enhance anti-tumor immunity with other Astellas therapies including chimeric antigen receptor-based (CAR) technologies. Astellas will have the exclusive option to license any development candidates generated as part of the collaboration.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.